Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 522-529

  Zorić, Arijana ^a   Horvat, Andela ^a   Slade, Neda ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROTEIN P53; PROTEIN P53ALPHA; PROTEIN P53BETA; PROTEIN P53GAMMA; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN TAP63; TRANSACTIVATOR PROTEIN TAP73ALPHA; TRANSACTIVATOR PROTEIN TAP73BETA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION;

APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HALF-LIFE; HUMANS; LUCIFERASES, RENILLA; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STABILITY; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84874765906     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs370     Document Type: Article

References (40)

1. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
2. Hainaut, P. et al. (2000) p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 77, 81-137.
3. Kaghad, M. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-819.
4. Yang, A. et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell, 2, 305-316.
5. Donehower, L.A. et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
6. Moll, U.M. et al. (2004) p63 and p73: roles in development and tumor formation. Mol. Cancer Res., 2, 371-386.
7. Murray-Zmijewski, F. et al. (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ., 13, 962-972.
8. Bourdon, J.C. et al. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev., 19, 2122-2137.
9. Slade, N. et al. (2011) Targeting p73-a potential approach in cancer treatment. Curr. Pharm. Des., 17, 591-602.
10. Hainaut, P. et al. (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res., 25, 151-157.
11. Di Como, C.J. et al. (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol., 19, 1438-1449.
12. Zaika, A.I. et al. (2002) DeltaNp73, a dominant-negative inhibitor of wildtype p53 and TAp73, is up-regulated in human tumors. J. Exp. Med., 196, 765-780.
13. Gaiddon, C. et al. (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol., 21, 1874-1887.
14. Strano, S. et al. (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem., 275, 29503-29512.
15. Stiewe, T. et al. (2002) Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem., 277, 14177-14185.
16. Slade, N. et al. (2004) DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ., 11, 357-360.
17. Flores, E.R. et al. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature, 416, 560-564.
18. Grob, T.J. et al. (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ., 8, 1213-1223.
19. Marcel, V. et al. (2010) p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene, 29, 2691-2700.
20. Aoubala, M. et al. (2011) p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ., 18, 248-258.
21. Fujita, K. et al. (2009) p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat. Cell Biol., 11, 1135-1142.
22. Marcel, V. et al. (2012) Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ., 19, 816-826.
23. Nakagawa, T. et al. (2002) Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol. Cell. Biol., 22, 2575-2585.
24. Melino, G. (2011) p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ., 18, 1487-1499.
25. Courtois, S. et al. (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene, 21, 6722-6728.
26. Goldschneider, D. et al. (2006) Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res., 34, 5603-5612.
27. Graupner, V. et al. (2009) Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle, 8, 1238-1248.
28. Renzing, J. et al. (1995) p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene, 10, 1865-1868.
29. Avery-Kiejda, K.A. et al. (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNAdamaging agent cisplatin. Clin. Cancer Res., 14, 1659-1668.
30. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
31. Jost, C.A. et al. (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature, 389, 191-194.
32. Chen, J. et al. (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev., 23, 278-290.
33. Ghosh, A. et al. (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell. Biol., 24, 7987-7997.
34. Scoumanne, A. et al. (2005) Structural basis for gene activation by p53 family members. Cancer Biol. Ther., 4, 1178-1185.
35. Rodriguez, M.S. et al. (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol., 20, 8458-8467.
36. Camus, S. et al. (2012) The p53 isoforms are differentially modified by Mdm2. Cell Cycle, 11, 1646-1655.
37. Hofstetter, G. et al. (2010) Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene, 29, 1997-2004.
38. Bourdon, J.C. et al. (2011) p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res., 13, R7.
39. Marabese, M. et al. (2008) Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur. J. Cancer, 44, 131-141.
40. Hofstetter, G. et al. (2012) The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer. Int. J. Gynecol. Cancer, 22, 372-379.